Porcine neural cell product-PD

Drug Profile

Porcine neural cell product-PD

Alternative Names: NeuroCell-PD

Latest Information Update: 26 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Diacrin; Genzyme Corporation
  • Developer Diacrin
  • Class Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Dopaminergic cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 25 Jan 2017 Discontinued - Phase-II for Parkinson's disease in USA (Intracerebral)
  • 06 Aug 2002 Suspended - Phase-II for Parkinson's disease in USA (Intracerebal)
  • 27 Mar 2001 Data have been added to the therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top